Advertisement

Topics

Latest "Grubb & Ellis Company" News Stories

03:05 EST 19th January 2019 | BioPortfolio

Here are the most relevant search results for "Grubb & Ellis Company" found in our extensive news archives from over 250 global news sources.

More Information about Grubb & Ellis Company on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Grubb & Ellis Company for you to read. Along with our medical data and news we also list Grubb & Ellis Company Clinical Trials, which are updated daily. BioPortfolio also has a large database of Grubb & Ellis Company Companies for you to search.

Showing "Grubb Ellis Company" News Articles 1–25 of 18,000+

Friday 18th January 2019

Ping An Good Doctor's 'Voiceprint Lock' Achieves Login Success Rate Close to 99%

Leading the Industry in Voiceprint Recognition Technology SHANGHAI, Jan. 18, 2019 /PRNewswire/ -- China's leading one-stop healthcare ecosystem platform Ping An Health Medical Technology Company Limited ("Ping An Good Doctor", or the "Company", stock code: 01833.HK) has announced that the "Voiceprint Login System" ("Voicepri...


Photo of Cigna Building Blessings in a Backpack in Orlando Available on Business Wire's Website and the Associated Press Photo Network

A photo is available on Business Wire's website and the Associated Press photo network of Cigna and Express Scripts employees in Orlando celebrating the combination of the two companies by filling 1,500 backpacks with food for children at the Metrowest and Westpointe Elementary Schools in Orlando. The event marked the beginning of a new global $25 million ...

Photo of Cigna Building Blessings in a Backpack in Phoenix Available on Business Wire's Website and the Associated Press Photo Network

A photo is available on Business Wire's website and the Associated Press photo network of Cigna and Express Scripts employees at the Cigna Norterra office celebrating the combination of the two companies by filling 1,500 backpacks with food for children at the Nevitt Elementary School in Tempe, Arizona. The event marked the beginning of a new global $25 mi...


Photo of Cigna Building Blessings in a Backpack in Franklin Lakes, N.J. Available on Business Wire's Website and the Associated Press Photo Network; Food Going to Bronx, N.Y. School

A photo is available on Business Wire's website and the Associated Press photo network of employees at the Express Scripts office in Franklin Lakes, N.J. celebrating the company’s combination with Cigna by filling backpacks with food for children at Public School 20 in the Bronx, New York. The event marked the beginning of a new global $25 million progra...

Precision Therapeutics Receives $1,370,000 Investment from CEO and Director, Carl Schwartz

Precision Therapeutics (NASDAQ:AIPT) announced that its chief executive officer and director, Carl Schwartz, has made an additional investment of $1,000,000 in the Company, effective January 8, 2019. As quoted in the press release: “I have long been a firm believer in the vast potential of Precision Therapeutics and my most fervent demonstration of this belief … Continued The post Precisio...

Bavarian Nordic Announces Exercise of USD 44 Million Option by the U.S. Government

Bavarian Nordic (OMX:BAVA,OTC:BVNRY) announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA) have exercised another option under the ongoing contract for freeze-dried MVA-BN smallpox vaccine. As quoted in the press release: The option, valued at USD 44 million, will cover qualification of the new fill-finish facility, currently being established at the Company...

Lilly’s Lartruvo Fails to Meet Primary Endpoints in Phase 3 Soft Tissue Sarcoma Study

INDIANAPOLIS, Jan. 18, 2019 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today reported that the results of ANNOUNCE, the Phase 3 study of LARTRUVO® (olaratumab), in combination with doxorubicin in patients with advanced or metastatic soft tissue sarcoma (STS), did not confirm the clinical benefit of LARTRUVO in combination with doxorubicin as compared to d...

TransCanna's Affiliate TCM Distribution, Inc. Receives State of California Temporary Distributor License

Vancouver, British Columbia--(Newsfile Corp. - January 18, 2019) - Transcanna Holdings Inc. (CSE: TCAN) ("TransCanna" or the "Company") is pleased to announce that TCM Distribution, Inc. ("TCMD"), ...

Immunomedics Receives CRL from FDA for Sacituzumab Govitecan BLA Seeking Accelerated Approval for Treatment of Metastatic TNBC

MORRIS PLAINS, N.J., Jan. 17, 2019 (GLOBE NEWSWIRE) — Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) seeking accelerate...

Cardiol Therapeutics Inc. Closes Over-Allotment

Cardiol Therapeutics Inc. (TSX:CRDL)  ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical cannabidiol products and targeted therapies for heart failure and cancer, announced today that the underwriters for the Company's initial public offering (the "Offering") have exercised their over-allotment option (the "Over-Allotment Option") to purchase an ad...

Synmosa Biopharma Corp 4114 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 23102018] Prices from USD $250

SummarySynmosa Biopharma Corp Synmosa is a pharmaceutical company that manufactures, markets and distributes generic medicines. The company produces nonpharmaceutical products such as cosmeceutical and nutrition products, and food supplements in effervescent tablet and granule forms. It offers products in the therapeutic areas of cardiovascular, respiratory, urology, sex hormone, gynecology and ca...

Dr. John Mendlein to Transition to an Advisory Role at Moderna and Join Flagship Pioneering as an Executive Partner

Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that John Mendlein, Ph.D., President of Corporate and Product Strategy, will be leaving the Company effective February 1, 2019 to join Flagship Pi...

Can-Fite BioPharma Announces Registered Direct Offering

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that it has entered into a definitive agreement with a single institutional investor to receive gross proceeds of approximately $2.35 million. ...

Lilly: Phase 3 Soft Tissue Sarcoma Study Fails Not Meet Primary Endpoints

INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) said that a late-stage trial of a treatment for sarcoma did not meet the primary endpoints. It is suspending promotion of lartruvo. It expects ...

Autifony Therapeutics achieves first milestone in agreement with Boehringer Ingelheim for a novel therapeutic approach to a range of CNS disorders

Stevenage, UK – 18 January 2019 – Autifony Therapeutics Limited (“Autifony”), a clinical stage company developing new drugs to treat serious disorders of the nervous system, today announced that the first milestone has successfully been achieved under Autifony’s option agreement with Boehringer Ingelheim. As announced previously, Boehringer Ingelheim acquired an exc...

MOLOGEN AG: Next generation TLR9 agonist product family EnanDIM(R) featured in renowned JITC journal

DGAP-News: MOLOGEN AG / Key word(s): Study 18.01.2019 / 09:48 The issuer is solely responsible for the content of this announcement. PRESS RELEASE N 2 / 2019 of 01/18/2019 MOLOGEN AG: Next generation TLR9 agonist product family EnanDIM(R) featured in renowned JITC journal Berlin, 18 January 2019 - The biopharmaceutical company MOLOGEN AG reported that its scientific article on EnanDI...

Xbrane Biopharma announces acceptance of initiation of Xlucane clinical trial in the US

Press release2019-01-18 The Food and Drug Administration (FDA) and the Central Ethics Committee in the United States have accepted Xbranes IND application for initiation of the Xplore trial, a phase III trial with Xlucane, a ranibizumab (Lucentis®) biosimilar candidate. "It is with great satisfaction we can announce acceptance from the FDA and the Central Ethics Committee...

Bavarian Nordic Announces Exercise of USD 44 Million Option by the U.S. Government under Contract for Freeze-dried MVA-BN® Smallpox Vaccine

COPENHAGEN, Denmark, January 18, 2019 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA) have exercised another option under the ongoing contract for freeze-dried MVA-BN® smallpox vaccine. The option, valued at USD 44 million, will cover qualification of the new fill-finish facility, currentl...

ERYTECH Presents TRYbeCA-1 Trial-in-Progress Poster at the 2019 ASCO GI Annual Meeting

LYON, France and CAMBRIDGE, Mass., Jan. 18, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, announced that a poster entitled "TRYbeCA-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemoth...

MICROSCOPIO STEREOSCOPICO STEREO RIPARAZIONE ELETTRONICA 20X INGRANDIMENTO 3D1ST

EUR 94,49Scadenza: venerdì feb-1-2019 23:05:02 CETCompralo Subito per soli: EUR 94,49Compralo Subito | Aggiungi all’elenco degli oggetti che osservi Biotech365 : MICROSCOPIO STEREOSCOPICO STEREO RIPARAZIONE ELETTRONICA 20X INGRANDIMENTO 3D1ST BioMarketplace You want to propose your products or a Biotech Company, … Continue reading →

#Cannabisstocks: Aphria (TSX: APHA and NYSE: APHA) and UNOapp to Partner on Technology and Analytics Solutions for the Adult-Use Cannabis Industry

LEAMINGTON, ON - January 18, 2019 (Investorideas.com Newswire) Aphria Inc. ("Aphria" or the "Company") (TSX: APHA and NYSE: APHA) has recently entered into an exclusive agreement (the "Agreement") with Toronto-based UNOapp Inc. ("UNOapp") to collaborate on the development of technology and analytics solutions for Canada's adult-use cannabis industry.

#Cannabisstocks: Lifestyle Delivery Systems Inc. (CSE: LDS) (OTCQX: LDSYF) Announces Annual Manufacturing License Issued to CSPA Group Inc.

VANCOUVER, British Columbia - January 18, 2019 (Investorideas.com Newswire) Lifestyle Delivery Systems Inc. (CSE: LDS), (OTCQX: LDSYF), (Frankfurt: LD6, WKN: A14XHT) ("LDS" or the "Company") announces that CSPA Group, Inc. ("CSPA") was issued an Annual Manufacturing License by the California Department of Public Health.

Thursday 17th January 2019

Carena Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 14122018] Prices from USD $250

SummaryCarena Inc Carena is a telemedicine solution provider that serves patients through phone, webcam, or house call to diagnose and treat injuries and illness. The center provides virtual house call and inhome care services integrated with other company sponsored health and productivity initiatives such as nurse lines, wellness programs, and care management, and followingup with member's primar...

What’s Next? Eli Lilly’s Lartruvo Flunks Sarcoma Trial

Eli Lilly and Company’s ANNOUNCE Phase III clinical trial of Lartruvo (olaratumab) in advanced or metastatic soft tissue sarcoma (STS) failed to meet the primary endpoints of overall survival (OS).

Mount Sinai Partners with Paradigm Biopharmaceuticals Ltd. and ReqMed Company, Ltd. to repurpose drug to battle rare MPS diseases

(The Mount Sinai Hospital / Mount Sinai School of Medicine) The Icahn School of Medicine at Mount Sinai has entered into two exclusive licenses to develop the drug pentosan polysulfate sodium for the treatment of mucopolysaccharidosis (MPS).


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks